Needle-Free Flu Protection for Children and Adolescents
Needle-Free Flu Protection for Children and Adolescents
In 2026, families in New South Wales will have access to a needle-free influenza (flu) vaccine for young children.
The intranasal FluMist nasal spray vaccine will be free for children aged 2 to under 5 years. It will also be available privately for children and teens up to 18 years of age. FluMist will allow parents to protect their young children from severe flu without the stress of a needle, as it is delivered via a painless and simple nasal spray.
Why is it important to vaccinate my child for the flu?
Although flu can be mild for some, it can also cause serious illness and hospitalisation, even in healthy children. Vaccination helps protect them from severe disease and reduces community spread, helping keep vulnerable people safer.
How does it work?
FluMist is a live-attenuated vaccine, meaning that it contains weakened strains of flu viruses that train the immune system to recognise the viruses. but cannot cause illness in healthy individuals.
It is given as a quick spray into each nostril and is rapidly absorbed. If a child sneezes or blows their nose afterwards, the vaccine will still work and does not need to be repeated.
Common side effects are mild and short-lived, such as a runny nose or other mild respiratory symptoms. The vaccine is not suitable for children who are moderately or severely immunocompromised and should be used with caution for those who are close contacts of people with significant immunocompromise.
Where can my child get the intranasal vaccine?
The intranasal vaccine will be available for free at the GP for children aged two to under five and can be purchased privately for children aged five to under eighteen at GPs and certain pharmacies.
Find out more information about the intranasal flu vaccine in the National Centre for Immunisation Research and Surveillance (NCIRS) Frequently Asked Questions resource.
Immunisation Weekly Update: Welcome to our weekly Immunisation Update. In this week’s update, read about: New interim ATAGI advice for RSV-specific monoclonal antibodies for Indigenous infant and children Counterfeit rabies vaccine reported in India: Ensure travellers are fully protected Updated NSW Cold Chain Resources Australian Immunisation Handbook: New dengue chapter…
Best Practice Premier: Action Required for CDA Document Viewing Google is removing support for XSLT technology from Chromium on 17 November 2026. Chromium is the browser engine used by Google Chrome and Microsoft WebView2. Bp Premier uses WebView2 to display CDA documents, including information from My Health Record and MediBridge…
Community Notice from CanTEST: Medetomidine found in green ‘S 90 3’ pill 4 November 2026 CanTEST Health & Drug Checking Service has published a Community Notice on social media. It is also viewable as a webpage on The Know. ‘A green rectangular pill marked ‘S 90 3’ and two break lines splitting…
Supporting Patient Choice for Planned Surgery and Shorter Wait Times In accordance with section 68 of the Health Services Act 1997, patients may access elective surgery at a hospital other than their local hospital. Discussing available options for surgery may help suitable patients access surgery sooner where they are willing…
New Opioid Treatment Program legislative requirements and supporting resources On 5 November 2026, the Medicines, Poisons and Therapeutic Goods Regulation 2026 commenced, introducing changes to the management of patients receiving treatment under the NSW Opioid Treatment Program (OTP). The new legislative framework strengthens safeguards for patients and the community, supports…
Immunisation Weekly Update: Welcome to our weekly Immunisation Update. In this week’s update, read about: Giving MenB with Other Vaccines? Australian Evidence Supports the Approach Empowering immunisation conversations A spotlight on whooping cough Feedback Education Giving MenB with Other Vaccines? Australian Evidence Supports the Approach A recent Australian study published…